Orchestra BioMed Completes $35M Royalty Financing, Gains $15M from Ligand and $20M from Medtronic
Orchestra BioMed received a $15 million tranche from Ligand Pharmaceuticals, completing its $35 million royalty financing commitment and bringing total Ligand funding to $40 million. Combined with a separate $20 million Medtronic investment on May 1, 2026, the financing supports pivotal trials for AVIM Therapy and Virtue SAB.
1. Strategic Financing from Ligand
Orchestra BioMed received a $15 million payment from Ligand, completing the scheduled tranche under their revenue participation agreement and fulfilling Ligand’s $35 million royalty financing commitment. This latest tranche brings total Ligand capital to $40 million, including a $5 million equity private placement completed in August 2025.
2. Medtronic Investment Support
On May 1, 2026, Orchestra BioMed secured a separate $20 million investment from Medtronic to advance its cardiovascular programs. This injection of capital complements Ligand’s financing and reflects continued confidence from market-leading medical device partners.
3. Funding Allocation for Pivotal Trials
The combined $35 million in fresh strategic capital will fund ongoing pivotal trials for AVIM Therapy and the Virtue Sirolimus AngioInfusion Balloon. Key activities include accelerated enrollment in the BACKBEAT trial, initiation of Virtue trial patient recruitment, and partnership realignment with Terumo.
4. Clinical and Corporate Milestones Outlook
Orchestra BioMed expects to leverage this capital to meet upcoming clinical and corporate milestones, including interim data readouts for its late-stage cardiovascular therapies. These results will be critical in determining the commercial potential and long-term value of both AVIM Therapy and Virtue SAB.